Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancerMotonobu Saito(National Cancer Centre Japan), Akiteru Goto(Akita University)Molecular and Clinical OncologyDecember 12, 201710.3892/mco.2017.1536Cited by 29SaveCiteExport RISWatch citationsRelated PapersTargeted Disruption of Ing2 Results in Defective Spermatogenesis and Development of Soft-Tissue Sarcomas|PLoS ONE|2010|58